JPM Identifies CN Healthcare Sector Decline as Buying Opportunity, Increases Price Targets for INNOVENT BIO and WUXI XDC
Market Overview: JPMorgan's report indicates that the Chinese healthcare sector has seen a retreat due to price negotiations and profit-taking, but the fundamentals remain strong, presenting a buying opportunity for 2026.
Stock Recommendations: The broker favors biotechnology and CXO sectors, highlighting top picks such as INNOVENT BIO, SKB BIO-B, WUXI APPTEC, and WUXI XDC, along with a positive outlook for MEDBOT-B in medical technology.
Target Price Adjustments: JPMorgan has adjusted target prices for several stocks, lowering AKESO's target from HKD166 to HKD149 while maintaining an Overweight rating, and slightly increasing INNOVENT BIO's target from HKD110 to HKD111.
Performance Metrics: The report includes short selling data for the highlighted stocks, indicating varying levels of short interest, with WUXI APPTEC and WUXI XDC showing significant short selling ratios.
Trade with 70% Backtested Accuracy
Analyst Views on 01801
About the author
<Midday Update> HSI Rises by 468 Points; HSTI Gains 177 Points; XIAOMI Surges Over 5%; BABA Increases Over 4%; TENCENT Climbs Over 3%
Market Performance: The Hang Seng Index (HSI) rose by 468 points (1.9%) to 25,789, while the Hang Seng Tech Index (HSTI) increased by 177 points (3.7%) to 4,973, and the Hang Seng China Enterprises Index (HSCEI) gained 187 points (2.2%) to 8,638.
Top Gainers: Notable stock performances included JD Logistics, which surged 21.3%, JD up 8.5%, and Trip.com rising 7.0%. Major companies like Xiaomi, Alibaba, and Tencent also saw significant increases in their stock prices.
Short Selling Activity: High short selling volumes were reported for several stocks, with Alibaba and JD having short selling ratios of 16.072% and 50.972%, respectively, indicating investor caution despite their price increases.
Other Notable Movements: Stocks like TransThera and Bayzed Health experienced substantial gains of 34.9% and 21.5%, respectively, while Chinahongqiao saw a decline of 3.3%, reflecting varied performance across different sectors.
<Midday Update> HSI Ends Midday at 25,462, Gaining 212 Points; HSTI Remains Unchanged at 4,829; SINO BIOPHARM Rises More Than 5%; KINETIC DEV Reaches New Peaks
Market Performance: The Hang Seng Index (HSI) rose by 212 points (0.8%) to 25,462, while the Hang Seng China Enterprises Index (HSCEI) gained 20 points (0.2%) to 8,504.
Active Heavyweights: Notable movements included Meituan down 1.7%, Xiaomi up 1.6%, HKEX up 1.4%, Alibaba down 1.2%, and Tencent up 0.5%.
Top Gainers: Significant gainers included Sino Biopharm (+5.9%), AIA (+4.0%), Wharf REIC (+3.6%), and HSBC Holdings (+3.1%).
Notable Declines: WestChinaCement saw a sharp decline of 23.8%, while IFBH experienced a substantial increase of 24.3%.
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Resumes Coverage of INNOVENT BIO with Overweight Rating; Key Catalysts for CN Biotech Sector Expected in Second Half of 2026
China's Biotech Sector Outlook: Morgan Stanley reports that China's biotech sector is stabilizing with a resilient innovation base and ongoing financing recovery, but faces challenges due to geopolitical uncertainties and limited investment themes in 1H26.
Market Fluctuations and Future Growth: The sector is expected to experience range-bound fluctuations in 1H26, with potential for clearer stock price direction in 2H26 as meaningful data releases and licensing transactions emerge.
Investment Strategy: A broader de-risking sector rotation is anticipated, putting pressure on high Beta biotech sectors, while capital reallocation and favorable valuations may support future growth.
Coverage on INNOVENT BIO: Morgan Stanley has reinitiated coverage on INNOVENT BIO with an Overweight rating and a target price of HKD130, along with adjustments to target prices for other stocks.
HSI Closes Down 384 Points on Futures Settlement Day; Declines in Tech, Auto, Consumer, and Pharma Sectors
Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.
CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.
Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.
Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.
<Full-day Summary> HSI Falls by 491 Points; HSTI Declines by 114 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, MTR CORPORATION, SINOPHARM Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 491 points (1.8%) to close at 26,590, with significant declines also seen in the HSTI and HSCEI, which dropped 114 points (2.1%) and 189 points (2.1%) respectively, amid a market turnover of $250.99 billion.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, Alibaba, and Xiaomi experienced notable declines, with Meituan down 4.2% and Tencent down 3.3%, reflecting a trend of short selling across these companies.
Constituents on the Move: Several constituents saw significant price changes, including Sino Biopharma and Hansoh Pharma, which dropped 6.6% and 6.4% respectively, while WH Group rose by 4.4%, reaching a new high.
Other Notable Stocks: Stocks such as MIRXES-B and CTG Duty-Free faced substantial losses, with MIRXES-B down 21.7%, while KB Laminates and CNBM saw gains of 12.4% and 10.5%, respectively, also hitting new highs.
<Midday Update> HSI Rises by 468 Points; HSTI Gains 177 Points; XIAOMI Surges Over 5%; BABA Increases Over 4%; TENCENT Climbs Over 3%
Market Performance: The Hang Seng Index (HSI) rose by 468 points (1.9%) to 25,789, while the Hang Seng Tech Index (HSTI) increased by 177 points (3.7%) to 4,973, and the Hang Seng China Enterprises Index (HSCEI) gained 187 points (2.2%) to 8,638.
Top Gainers: Notable stock performances included JD Logistics, which surged 21.3%, JD up 8.5%, and Trip.com rising 7.0%. Major companies like Xiaomi, Alibaba, and Tencent also saw significant increases in their stock prices.
Short Selling Activity: High short selling volumes were reported for several stocks, with Alibaba and JD having short selling ratios of 16.072% and 50.972%, respectively, indicating investor caution despite their price increases.
Other Notable Movements: Stocks like TransThera and Bayzed Health experienced substantial gains of 34.9% and 21.5%, respectively, while Chinahongqiao saw a decline of 3.3%, reflecting varied performance across different sectors.
<Midday Update> HSI Ends Midday at 25,462, Gaining 212 Points; HSTI Remains Unchanged at 4,829; SINO BIOPHARM Rises More Than 5%; KINETIC DEV Reaches New Peaks
Market Performance: The Hang Seng Index (HSI) rose by 212 points (0.8%) to 25,462, while the Hang Seng China Enterprises Index (HSCEI) gained 20 points (0.2%) to 8,504.
Active Heavyweights: Notable movements included Meituan down 1.7%, Xiaomi up 1.6%, HKEX up 1.4%, Alibaba down 1.2%, and Tencent up 0.5%.
Top Gainers: Significant gainers included Sino Biopharm (+5.9%), AIA (+4.0%), Wharf REIC (+3.6%), and HSBC Holdings (+3.1%).
Notable Declines: WestChinaCement saw a sharp decline of 23.8%, while IFBH experienced a substantial increase of 24.3%.
<M Stanley Analysis> Ratings and Target Prices for CN Biopharma Stocks (Table)
Stock Performance: Several Hong Kong stocks experienced declines, with EVEREST MED down 2.095%, INNOVENT BIO down 1.090%, and ZAI LAB down 2.304%.
Short Selling Data: INNOVENT BIO had the highest short selling at $213.64M, with a ratio of 28.305%, indicating significant market skepticism.
Analyst Ratings: M Stanley has reinitiated coverage on INNOVENT BIO with an "Overweight" rating, suggesting potential growth in the Chinese biotech sector in the second half of 2026.
Price Targets Adjustments: Price targets for EVEREST MED and VISEN PHARMA-B were adjusted downwards, reflecting changing market conditions and expectations.
M Stanley Resumes Coverage of INNOVENT BIO with Overweight Rating; Key Catalysts for CN Biotech Sector Expected in Second Half of 2026
China's Biotech Sector Outlook: Morgan Stanley reports that China's biotech sector is stabilizing with a resilient innovation base and ongoing financing recovery, but faces challenges due to geopolitical uncertainties and limited investment themes in 1H26.
Market Fluctuations and Future Growth: The sector is expected to experience range-bound fluctuations in 1H26, with potential for clearer stock price direction in 2H26 as meaningful data releases and licensing transactions emerge.
Investment Strategy: A broader de-risking sector rotation is anticipated, putting pressure on high Beta biotech sectors, while capital reallocation and favorable valuations may support future growth.
Coverage on INNOVENT BIO: Morgan Stanley has reinitiated coverage on INNOVENT BIO with an Overweight rating and a target price of HKD130, along with adjustments to target prices for other stocks.
HSI Closes Down 384 Points on Futures Settlement Day; Declines in Tech, Auto, Consumer, and Pharma Sectors
Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.
CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.
Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.
Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.
<Full-day Summary> HSI Falls by 491 Points; HSTI Declines by 114 Points; MEITUAN, PING AN Drop Over 4%; TENCENT Decreases Over 3%; WH GROUP, HENDERSON LAND, CKI HOLDINGS, MTR CORPORATION, SINOPHARM Reach New Peaks; Market Turnover Increases
Market Performance: The Hang Seng Index (HSI) fell by 491 points (1.8%) to close at 26,590, with significant declines also seen in the HSTI and HSCEI, which dropped 114 points (2.1%) and 189 points (2.1%) respectively, amid a market turnover of $250.99 billion.
Active Heavyweights: Major stocks like Meituan, Ping An, Tencent, Alibaba, and Xiaomi experienced notable declines, with Meituan down 4.2% and Tencent down 3.3%, reflecting a trend of short selling across these companies.
Constituents on the Move: Several constituents saw significant price changes, including Sino Biopharma and Hansoh Pharma, which dropped 6.6% and 6.4% respectively, while WH Group rose by 4.4%, reaching a new high.
Other Notable Stocks: Stocks such as MIRXES-B and CTG Duty-Free faced substantial losses, with MIRXES-B down 21.7%, while KB Laminates and CNBM saw gains of 12.4% and 10.5%, respectively, also hitting new highs.
